Arca
Skip to content
Tools
Tools

TNFSF13B: Tumor necrosis factor ligand superfamily member 13B

Cytokine that binds to TNFRSF13B/TACI and TNFRSF17/BCMA.

  • Drugs that act on it: 7
  • Approved: 1
  • In phases 1 to 3: 6
  • Sponsors: 6

Who is on it, and how far along

Every drug ChEMBL records acting on TNFSF13B, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 3
  • Protein or peptide 3
  • Other 1

Approved1

  • Belimumab

Phase 33

  • Atacicept
  • Blisibimod
  • Tabalumab

Phase 23

  • Tibulizumab
  • Briobacept
  • Rozibafusp alfa

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • Anthera Pharmaceuticals114%
    • Zura Bio Inc114%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Tumor necrosis factor ligand superfamily member 13B inhibitor.
    BelimumabApprovedGSKAntibodyInhibitor28
    AtaciceptPhase 3Vera TherapeuticsProtein or peptideInhibitor4
    BlisibimodPhase 3Anthera PharmaceuticalsOtherInhibitor0
    TabalumabPhase 3Eli LillyAntibodyInhibitor0
    TibulizumabPhase 2Zura Bio IncAntibodyInhibitor2
    BriobaceptPhase 2—Protein or peptideInhibitor0
    Rozibafusp alfaPhase 2AmgenProtein or peptideInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 14 in all, from ClinicalTrials.gov.
    Childhood-onset Lupus Nephritis Initial Glucocorticoid-dose Harmonization Trial (LIGHT Trial)BelimumabPhase 4RecruitingPeking Union Medical College HospitalJul 22, 2026
    PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus NephritisBelimumabPhase 4RecruitingAurinia Pharmaceuticals Inc.May 28, 2026
    Belimumab to Mobilise Memory B-cells From Secondary Lymhoid Organs to Improve Memory B-cell HLA-specificity Profiling to Support Delisting for Transplant Access in Highly-sensitizedBelimumabPhase 2RecruitingLeiden University Medical CenterApr 20, 2026
    The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil TreatmentBelimumabPhase 2RecruitingNanjing University School of MedicineJan 14, 2026
    Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy TrialBelimumabPhase 4RecruitingNephroNet, Inc.Nov 6, 2025
    Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyBelimumabPhase 2RecruitingNYU Langone HealthAug 24, 2025
    Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung DiseaseBelimumabPhase 4RecruitingTongji HospitalJul 22, 2025
    A Prospective Comparative Study Involving Multiple Units to Evaluate the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythematosus.Belimumab—Not yet recruitingYipeng LiuJul 17, 2025
    Monthly Dosing of Atacicept in IgANAtaciceptPhase 2Active, not recruitingVera Therapeutics, Inc.Jun 13, 2025
    Tibulizumab Skin Healing and Inflammation Evaluation for Lasting DefenseTibulizumabPhase 2Active, not recruitingZura Bio IncMay 29, 2025
    Atacicept in Multiple Glomerular DiseasesAtaciceptPhase 2RecruitingVera Therapeutics, Inc.May 21, 2025
    Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)TibulizumabPhase 2Active, not recruitingZura Bio IncFeb 24, 2025
    A Rollover Study to Evaluate the Long-Term Safety and Efficacy of AtaciceptAtaciceptPhase 2Enrolling by invitationVera Therapeutics, Inc.Nov 5, 2024
    Atacicept in Subjects With IgA NephropathyAtaciceptPhase 3Active, not recruitingVera Therapeutics, Inc.Jan 20, 2021

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2364158, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-19. Gene name, function (UniProt Q9Y275, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.